Scholarlink

Background <p>This study aimed to assess the associations of roxadustat with changes in serum trace element levels and with hypothyroidism in hemodialysis (HD) patients.</p> Methods <p>A total of 34 patients on HD who received weekly doses of darbepoetin-α or a continuous erythropoietin receptor activator once every 2 or 4&#xa0;weeks were switched to roxadustat (70&#xa0;mg, three times weekly). Levels of biomarkers for erythropoiesis and iron metabolism, trace elements (copper, zinc, and selenium), ceruloplasmin, and thyroid-stimulating hormone (TSH), free-triiodothyronine (T3), and free-tetraiodothyronine (T4) were measured in blood samples collected before the HD session on days 0 (switch to roxadustat treatment), 28, and 56.</p> Results <p>Serum copper and ceruloplasmin levels were significantly increased by roxadustat treatment on days 28 and 56, and serum selenium levels were lower on day 28. However, serum zinc levels were not changed over the 56&#xa0;days. Serum TSH levels were decreased on day 28, and they then increased to baseline on day 56. Serum free-T3 and free-T4 levels were significantly decreased from day 28 to day 56. Changes in roxadustat doses were associated with changes in serum TSH, free-T3, and free-T4 levels, whereas they were not associated with serum levels of trace elements.</p> Conclusions <p>Roxadustat may decrease serum TSH, free-T3, and free-T4 levels and increase serum copper and ceruloplasmin levels in HD patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Associations of roxadustat with copper elevation and hypothyroidism in patients on hemodialysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月29日

查看全文
  • Shugo Aoki,
  • Tomohiro Saito,
  • Shunsuke Yoshida,
  • Keigo Shibagaki,
  • Keiichi Hirao,
  • Toshiki Yuza,
  • Hirokazu Honda

摘要

Background

This study aimed to assess the associations of roxadustat with changes in serum trace element levels and with hypothyroidism in hemodialysis (HD) patients.

Methods

A total of 34 patients on HD who received weekly doses of darbepoetin-α or a continuous erythropoietin receptor activator once every 2 or 4 weeks were switched to roxadustat (70 mg, three times weekly). Levels of biomarkers for erythropoiesis and iron metabolism, trace elements (copper, zinc, and selenium), ceruloplasmin, and thyroid-stimulating hormone (TSH), free-triiodothyronine (T3), and free-tetraiodothyronine (T4) were measured in blood samples collected before the HD session on days 0 (switch to roxadustat treatment), 28, and 56.

Results

Serum copper and ceruloplasmin levels were significantly increased by roxadustat treatment on days 28 and 56, and serum selenium levels were lower on day 28. However, serum zinc levels were not changed over the 56 days. Serum TSH levels were decreased on day 28, and they then increased to baseline on day 56. Serum free-T3 and free-T4 levels were significantly decreased from day 28 to day 56. Changes in roxadustat doses were associated with changes in serum TSH, free-T3, and free-T4 levels, whereas they were not associated with serum levels of trace elements.

Conclusions

Roxadustat may decrease serum TSH, free-T3, and free-T4 levels and increase serum copper and ceruloplasmin levels in HD patients.